Skip to content
Peptide Atlas
All peptides

KPV

Tier 3 · Reported use
Also known as Lys-Pro-Val · alpha-MSH(11-13)

The strongest evidence present is Tier 1, comprising in vitro/human-cell studies (e.g.,1's work on human bronchial airway epithelium reporting dose-dependent NFκB inhibition, and2,14 antimicrobial studies). Beyond these, the body of evidence is dominated by Tier 2 animal and in vitro work (mouse colitis models per Dalmasso et al. 2008 and Kannengiesser et al. 2008, keratinocyte, contact-hypersensitivity and peritonitis studies) and Tier 3 vendor, dosing-guide, and community sources. Multiple sources agree there are zero completed human clinical trials, no pharmacokinetic data in any species, and no FDA/EMA/Health Canada approval for KPV. Note:5 (a cancer study) uses 'KPV' as a mouse genotype label and is unrelated to the Lys-Pro-Val tripeptide.

Half-life
Not recorded
Routes
Subcutaneous · Oral · Topical · Intranasal (claimed by dosing-guide source) · Intracolonic/rectal (animal studies)
Goals
healing · immune support
Cost / mg
Not recorded

How it works

According to vendor and reference sources, KPV is a three-amino-acid fragment (Lys-Pro-Val) taken from the tail end of the natural hormone alpha-MSH, and most sources describe it as calming inflammation(vendor claim). A Tier 1 study using human airway cells reported that KPV dose-dependently dampened NF-κB — a master switch for inflammation — and reduced inflammatory molecules. Many sources say it enters cells (especially inflamed gut cells) via a transporter called PepT1 and quiets pro-inflammatory signals like TNF-alpha, IL-1beta and IL-6. Sources disagree on whether KPV works by activating melanocortin receptors or independently of them; several state it does NOT bind those receptors and therefore, they report, does not cause tanning or sexual side effects.

Overview

Overview

KPV (Lys-Pro-Val; also written alpha-MSH(11-13)) is described by vendor and reference sources (1, one source, one source, one source, one source, one source, one source–one source) as a tripeptide derived from the C-terminal end of α-melanocyte-stimulating hormone (α-MSH), corresponding to residues 11-13. One reference source instead describes it as residues 193-195 of α-MSH(vendor claim). A clinician-oriented source20 notes that α-MSH is a thirteen-amino-acid neuropeptide produced in the pituitary that helps regulate immune function, fever and inflammation through the melanocortin receptor system, and that KPV comprises its last three residues.

Reported physical constants differ: a longevity reference source gives a molecular formula of C16H30N4O4, molecular weight 342.43 g/mol, and CAS number 67727-97-3; a vendor page lists 342.44 Da; and a dosing-guide lists 357.46 Da for an Ac-KPV-NH2 form(vendor claim).

What the research shows

A Tier 1 study1 reported that KPV suppresses inflammation in immortalised human bronchial airway epithelium, evoking dose-dependent inhibition of NFκB, matrix metalloproteinase-9 activity, and IL8 and eotaxin secretion, and that C-terminal truncations of αMSH retain anti-inflammatory properties with the minimum-effective sequence confined to K-P-V. Tier 2 animal work is the backbone of the gut literature: Dalmasso et al. 2008 (PMID 18061177; one source, one source10) established KPV as a PepT1-mediated anti-inflammatory tripeptide in DSS- and TNBS-induced mouse colitis, with oral KPV reducing colitis severity and pro-inflammatory cytokine expression, and Kannengiesser et al. Further Tier 2 studies report antimicrobial activity against S. aureus and C. albicans without reducing neutrophil killing capacity2,14, contact-hypersensitivity suppression and hapten-specific tolerance in mice13, reduced leukocyte accumulation in crystal-induced peritonitis independent of MC receptors12, protection of keratinocytes from particulate-matter-induced injury4, and improved outcomes in TNBS colitis with sustained-release hydrogel and delivery-matrix formulations6,7. A Tier 2 review9 describes α-MSH as a potent anti-inflammatory mediator across many animal models and states KPV retains almost all of the hormone's anti-inflammatory capacity while lacking pigmentary action.

Reported and explored uses

A vendor compound page states KPV has been explored in preclinical models of ulcerative colitis, Crohn's disease, atopic dermatitis, psoriasis, ocular inflammation and general skin inflammation(vendor claim). An AI-blog source18 reports the clearest research focus is inflammatory bowel disease, with emerging interest in wound healing, skin inflammation, metabolic inflammation and neuroinflammation. A consumer health site suggests potential benefits for inflammation, immune function and wound healing. Community reports describe KPV as one of the most-used anti-inflammatory peptides for IBD-spectrum gut conditions and chronic skin inflammation, often stacked with BPC-157, and used by some as a perceived safer alternative for people with mast cell activation syndrome. A dosing-focused blog notes many patients describe improved subjective sleep quality where sleep disruption is inflammation-mediated, while stressing KPV is not a primary sleep-promoting compound(vendor claim).

Regulatory and evidence status

A general health source19,20 reports the FDA has been evaluating KPV for wound healing and inflammatory conditions such as colitis, and a vendor page states that as of the dates it cites the FDA is evaluating KPV via the Pharmacy Compounding Advisory Committee for the Section 503A Bulk Drug Substances List. Multiple sources18,20 agree there are no completed human clinical trials, no pharmacokinetic data in any species, and no FDA/EMA/Health Canada approval for KPV as a standalone agent. An immune-signaling reference source clarifies that the one frequently cited human ulcerative-colitis trial actually studied K(D)PT, a related α-MSH-derived analog, not KPV itself(vendor claim).

Note on nomenclature

A Tier 2 cancer study (5, PMID 37161053) uses 'KPV' to denote a vimentin-knockout LSL-Kras;Tp53 mouse genotype in non-small-cell lung cancer research; its findings on vimentin, ferroptosis and withaferin A are unrelated to the Lys-Pro-Val tripeptide.

What the research shows

159 findings extracted from the 20 sources cited below, strongest evidence first within each group. Every one links to the source it came from.

What human studies found

Based on 3 human study findings, 21 animal findings, 10 in vitro findings, 2 expert opinion findings and 1 anecdotal finding.

  • human studyKPV suppresses inflammation in immortalised human bronchial airway epithelium1

  • human studyalpha-MSH reduced HIV replication in chronically and acutely infected human monocytes2

  • human studyVimentin is highly expressed in metastatic cancers, and its expression correlates with poor patient prognoses5

  • animalGenetic knockout of NLRP3 effectively alleviates vitiligo progression in mice3

  • animalMelanocyte-specific knockdown of NLRP3 using lysine-proline-valine (KPV)-modified deformable liposomes carrying Nlrp3 shRNA significantly alleviates vitiligo development3

  • animalThe alleviating effect of KPV on rats with TNBS-induced colitis was significantly improved by PMSP after intracolonic administration6

  • animalKPV has an anti-inflammatory effect on colitis7

  • animalThe enhanced therapeutic effect of the KPV/SH-PGA hydrogel on colitis was confirmed on 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced ulcerative colitis rats7

Show 29 more findings

  • animalColitis symptoms including body weight loss and the disease activity index score were obviously attenuated by rectally administering the KPV/SH-PGA hydrogel7

  • animalThe KPV/SH-PGA hydrogel prevented the colon shortening of TNBS-infused rats and decreased the colonic myeloperoxidase level7

  • animalThe morphology of the colon including the epithelial barrier, crypt, and intact goblet cells was recovered after KPV/SH-PGA hydrogel treatment7

  • animalIn vivo α-MSH has been shown to be anti-inflammatory in animal models of fever, irritant and allergic contact dermatitis, cutaneous vasculitis, fibrosis, in ocular, gastrointestinal, brain and allergic airway inflammation and arthritis9

  • animalOral administration of KPV reduces the incidence of DSS-induced colitis indicated by a decrease in pro-inflammatory cytokine expression10

  • animalOral administration of KPV reduces the incidence of TNBS-induced colitis indicated by a decrease in pro-inflammatory cytokine expression10

  • animalKPV (alpha-MSH 11-13) resulted in significant reduction in accumulation of polymorphonuclear leukocyte in the peritoneal cavity in a model of crystal-induced peritonitis in mice12

  • animalKPV exhibited anti-inflammatory effect in IL-1beta-induced peritonitis inflammation in mice12

  • animalKPV exhibited anti-inflammatory effect in mice with nonfunctional MC1-R (recessive yellow e/e mice)12

  • animalSystemic and topical application of KPV inhibited the sensitization and elicitation phase of contact hypersensitivity (CHS) in a mouse model13

  • animalKPV was able to induce hapten-specific tolerance in a mouse model of contact hypersensitivity13

  • animalalpha-MSH administered systemically during reperfusion reduced ischemia/reperfusion deficits in dogs16

  • animalalpha-MSH was more effective when given during both ischemia and reperfusion compared to reperfusion alone in dogs16

  • animalAnimal model studies have shown that KPV may reduce intestinal permeability and support mucosal healing18

  • animalMost research on KPV has been conducted in labs and on mice19

  • animalAnimal studies have found that KPV may help reduce the severity of ulcerative colitis20

  • in vitroKPV showed inhibitory influences against the gram-positive bacterium Staphylococcus aureus2

  • in vitroKPV showed inhibitory influences against the yeast Candida albicans2

  • in vitroTreatment with 50 μg/mL of KPV restored cell viability4

  • in vitroIn a three-dimensional (3D) skin model, KPV treatment effectively attenuated the inflammatory cell death induced by PM4

  • in vitroalpha-MSH peptides significantly inhibited S. aureus colony formation14

  • in vitroSmall concentrations of alpha-MSH peptides reduced viability and germ tube formation of C. albicans14

  • in vitroIn murine microglia cells, alpha-MSH reduced TNF-alpha and nitric oxide production in response to challenge16

  • in vitroIn human astrocytes, both alpha-MSH (1-13) and alpha-MSH (11-13) reduced TNF-alpha16

  • in vitroA 2007 study found that KPV could be a therapeutic agent for inflammatory bowel disease19

  • in vitroCell research suggests that the peptide could support skin healing20

  • expert opinionThe evidence base is primarily preclinical18

  • expert opinionHuman clinical trial data for KPV is very limited18

  • anecdotalsermorelin meaningfully improved my sleep17

How it works

Based on 11 human study findings, 24 animal findings, 38 in vitro findings, 15 expert opinion findings and 4 theoretical findings.

  • human studyKPV evoked dose-dependent inhibition of NFκB, matrix metalloproteinase-9 activity, IL8 and eotaxin secretion1

  • human studyKPV effect was associated with its nuclear import, IκBα stabilisation and suppressed nuclear translocation of YFP-tagged p65RelA1

  • human studyKPV suppresses NFκB signalling in airway epithelium by inhibition of p65RelA nuclear import1

  • human studyKPV interaction occurs between KPV and the Imp-α3 binding site on p65RelA which may involve blockade of the importin-α armadillo domain 7 and 81

  • human studyC-terminal truncations of αMSH possess anti-inflammatory properties with minimum-effective sequence confined to last 3 residues K-P-V1

  • human studyAnti-inflammatory effect of KPV extends over a range of concentrations which would exceed the kinetics of receptor-mediated effects1

  • human studyPEPTL1-mediated membrane transport of KPV raises the possibility that it mediates its effects by interacting with intracellular targets1

  • human studyalpha-MSH inhibited activation of the transcription factor NF-kappa B known to enhance HIV expression2

Show 84 more findings

  • human studyalpha-MSH is present in barrier organs such as gut and skin2

  • human studyPepT1 (oligopeptide transporter) is overexpressed in colonic epithelial cells of chronic ulcerative colitis8

  • human studyKPV triggers intracellular calcium responses in human keratinocytes, suggesting it has direct effects on skin cells independent of the traditional cyclic AMP pathway17

  • animalNLRP3 expression is significantly upregulated in the melanocytes of vitiligo patients and melanoma-Treg-induced vitiligo mouse model3

  • animalDownregulation of the E3 ligase β-TrCP1 in vitiligo melanocytes decreases K27-linked ubiquitination levels of NLRP33

  • animalDecreased K27-linked ubiquitination of NLRP3 weakens its interaction with the autophagy receptor NDP523

  • animalImpaired autophagic degradation of NLRP3 leads to hyperactivation of inflammation and pyroptosis in melanocytes3

  • animalKPV mice (vimentin knockout crossed with LSL-Kras; Tp53 mice) have attenuated tumor growth and improved survival compared with KPV mice5

  • animalWithaferin A (WFA) suppresses tumor growth and reduces tumor burden in the lung in KPV mice5

  • animalKPV and KPV cells fail to metastasize, suggesting that cell-autonomous metastasis requires mature vimentin intermediate filaments5

  • animalKPV cells upregulate genes associated with ferroptosis, an iron-dependent form of regulated cell death5

  • animalKPV cells have reduced glutathione peroxidase 4 (GPX4) levels, resulting in the accumulation of toxic lipid peroxides and increased ferroptosis5

  • animalVimentin is required for rapid tumor growth, metastasis, and protection from ferroptosis in NSCLC5

  • animalThe epithelial barrier of the colon effectively recovered following PMSP-KPV treatment6

  • animalPMSP-KPV modulated the gut flora, markedly augmenting the abundance of beneficial microorganisms in gut homeostasis6

  • animalThe mechanism by which PMSP-KPV induces a therapeutic effect may be associated with the inhibition of oxidative stress6

  • animalThe KPV/SH-PGA hydrogel decreased the expression of proinflammatory cytokines such as tumor necrosis factor α and interleukin 67

  • animalKPV is a tripeptide (Lys-Pro-Val) which possesses anti-inflammatory properties10

  • animalPepT1 is a di/tripeptide transporter normally expressed in the small intestine and induced in colon during inflammatory bowel disease (IBD)10

  • animalKPV is transported into cells by PepT110

  • animalThe antimigratory effect of KPV was not blocked by the MC3/4-R antagonist SHU911912

  • animalKPV is unlikely to mediate its effects through melanocortin receptors but is more likely to act through inhibition of IL-1beta functions12

  • animalKPV (alpha-MSH 11-13, the C-terminal tripeptide of alpha-MSH) is able to bind to MC-1R and modulate the function of APCs13

  • animalTolerance induction by KPV is mediated by the generation of CTLA4(+) and IL-10-producing T lymphocytes13

  • animalalpha-MSH modulates peripheral inflammation by acting on melanocortin receptors in host cells (macrophages, neutrophils) to inhibit production of proinflammatory agents16

  • animalalpha-MSH acts directly within the brain to modulate local inflammation16

  • animalIn dogs, ischemia/reperfusion in the posterior circulation causes inflammatory reactions and disturbance of function (decreases in auditory-evoked potentials)16

  • in vitroKPV is an endogenous peptide derived from α-melanocyte-stimulating hormone4

  • in vitroPM markedly suppresses HaCaT cell proliferation via cytotoxic effects4

  • in vitroPM induces a pro-inflammatory response by increasing IL-1β secretion4

  • in vitroKPV reduced IL-1β secretion disrupted by PM exposure4

  • in vitroKPV inhibited reactive oxygen species (ROS) production4

  • in vitroKPV decreased the expression of apoptosis-related proteins (Bax, Bcl-2, and cleaved caspase-3)4

  • in vitroKPV suppressed the redox-sensitive transcription factor nuclear factor-kappa B in PM-treated HaCaT cells4

  • in vitroKPV blocked ROS-mediated caspase-1 activation, reducing IL-1β secretion4

  • in vitroKPV protects keratinocytes by mitigating PM-induced pyroptosis4

  • in vitroKPV (Lys-Pro-Val) is the C-terminal sequence of α-MSH8

  • in vitroKPV can be delivered by PepT1 into cytosol in the intestine8

  • in vitroDCM-KPV accumulates in cytoplasm and nucleus of Caco-2 cells overexpressing PepT18

  • in vitroα-Melanocyte-stimulating hormone (α-MSH) is a potent anti-inflammatory mediator9

  • in vitroα-MSH affects various pathways regulating inflammatory responses such as NF-κB activation, expression of adhesion molecules, inflammatory cytokines, chemokine receptors, T-cell proliferation and activity and inflammatory cell migration9

  • in vitroKPV retains almost all of the anti-inflammatory capacity of the full hormone α-MSH9

  • in vitroSignificant similarities between anti-inflammatory signaling of α-MSH and KPV short peptides exist9

  • in vitroNanomolar concentrations of KPV inhibit the activation of NF-kappaB and MAP kinase inflammatory signaling pathways10

  • in vitroKPV reduces pro-inflammatory cytokine secretion in human intestinal epithelial cells and human T cells10

  • in vitroKPV acts via PepT1 expressed in immune and intestinal epithelial cells10

  • in vitroKPV is a carboxyl terminal tripeptide of alpha-MSH and represents one of the smallest minimal sequences reported to prevent inflammation11

  • in vitroNo elevation in cyclic AMP was detected in HaCaT or normal human keratinocytes in response to KPV peptides11

  • in vitroRapid and acute intracellular calcium elevation was observed in HaCaT keratinocytes in response to KPV in the presence of PIA, an adenosine agonist11

  • in vitroNormal keratinocytes responded to KPV peptides with intracellular calcium elevation11

  • in vitroStable transfection of Chinese hamster ovary cells with the MC-1 receptor showed that KPV peptides elevated intracellular calcium11

  • in vitroIn vitro, macrophage activation (determined as release of KC and IL-1beta) was not inhibited by KPV, unlike alpha-MSH and MTII12

  • in vitroKPV failed to increase cAMP accumulation, unlike MTII12

  • in vitroKPV modulates IgE production by IL-4 and anti-CD40 stimulated B lymphocytes in vitro13

  • in vitroKPV (carboxy-terminal tripeptide 11-13 of alpha-MSH) has antimicrobial influences against Staphylococcus aureus14

  • in vitroKPV has antimicrobial influences against Candida albicans14

  • in vitroalpha-MSH peptides reversed the enhancing effect of urokinase on S. aureus colony formation14

  • in vitroAntimicrobial influences of alpha-MSH peptides could be mediated by their capacity to increase cellular cAMP14

  • in vitroDideoxyadenosine (ddAdo), a potent adenylyl cyclase inhibitor, partly reversed the killing activity of alpha-MSH peptides14

  • in vitroalpha-MSH peptides enhanced killing of C. albicans and S. aureus by human neutrophils without reducing killing14

  • in vitroKPV is a fragment of alpha-MSH that modulates inflammation via three general actions: direct actions on peripheral host cells; actions on inflammatory cells within the brain to modulate local reactions; and descending neural anti-inflammatory pathways that control inflammation in peripheral tissues15

  • in vitroAlpha-MSH inhibits activation of NF-kappa B nuclear factor through preservation of I kappa B alpha, which binds to NF-kappa B and prevents its migration to the nucleus15

  • in vitroCells transfected with alpha-MSH plasmid vector are resistant to challenge with bacterial lipopolysaccharide15

  • in vitroAlpha-MSH modulates the production and action of proinflammatory cytokines in inflammatory cells in the periphery and within the central nervous system15

  • in vitroalpha-MSH peptides including KPV inhibited Staphylococcus aureus and Candida albicans at physiological concentrations, and importantly did not reduce the killing capacity of human neutrophils17

  • expert opinionKPV is an α-melanocyte stimulating hormone-derived tripeptide1

  • expert opinionKPV is a tripeptide (three amino acids: lysine, proline, valine) derived from the C-terminal end of alpha-melanocyte-stimulating hormone (alpha-MSH)17

  • expert opinionKPV has centered on its ability to reduce inflammation through the NF-kB pathway17

  • expert opinionKPV inhibits NF-kB activation, which reduces the downstream cascade of inflammatory signaling17

  • expert opinionKPV also signals through melanocortin receptors and calcium signaling pathways17

  • expert opinionKPV has demonstrated antimicrobial properties17

  • expert opinionPepT1 ferries KPV into intestinal and immune cells where it shuts down NF-kB and MAP kinase signaling17

  • expert opinionAt only three amino acids, it is one of the smallest peptides with demonstrated biological activity17

  • expert opinionKPV is a naturally derived tripeptide fragment of alpha-MSH18

  • expert opinionKPV stands for lysine-proline-valine, the three amino acids that form this short peptide chain18

  • expert opinionKPV is derived from the C-terminus of alpha-melanocyte-stimulating hormone, a naturally occurring hormone involved in immune regulation and inflammation control18

  • expert opinionKPV binds to melanocortin receptors, particularly MC1R and MC3R, which are expressed in immune cells and in the epithelial lining of the gut18

  • expert opinionBy engaging these receptors, KPV may downregulate pro-inflammatory signaling molecules including TNF-alpha, IL-6, and IL-1beta18

  • expert opinionKPV is a peptide made of three amino acids—lysine (K), proline (P), and valine (V)19

  • expert opinionKPV is created from a fragment of the α‑MSH hormone, which helps control inflammation20

  • theoreticalKPV is a fragment of alpha-melanocyte-stimulating hormone (alpha-MSH)2

  • theoreticalKPV (Lys-Pro-Val) is a tripeptide derived from α-MSH (α-melanocyte-stimulating hormone)7

  • theoreticalKPV, C-terminal tripeptide of α-MSH, lacks the entire sequence motif required for binding to any of the known MC-Rs9

  • theoreticalIt is not known if KPV operates via MC-1R or cyclic AMP for its anti-inflammatory properties11

Dosing

Based on 1 in vitro finding and 1 expert opinion finding.

  • in vitroAntimicrobial effects of alpha-MSH peptides occurred over a broad range of concentrations including the physiological (picomolar) range14

  • expert opinionKPV is typically administered as a pill, injection, or topical cream20

How the body handles it

Based on 1 human study finding, 3 animal findings, 3 in vitro findings and 1 expert opinion finding.

  • human studyA 2017 study in the Journal of Pharmaceutical Sciences tested topical KPV on human cadaver skin and found that it did not permeate well through skin19

  • animalKPV (Lys-Pro-Val) as a model drug was easily captured by PMSP through electrostatic interactions, thus retaining its bioactivity for a longer time under high temperature conditions6

  • animalKPV provided better stability to KPV when exposed to high temperature of 50 °C6

  • animalKPV solution is very unstable when rectally administered, compromising its therapeutic efficacy7

  • in vitroThe KPV/SH-PGA hydrogel presented a shear-thinning behavior, which was helpful for rectal administration7

  • in vitroOnly 30% of KPV was released from the KPV/SH-PGA hydrogel within 20 min, followed by a sustained-release behavior7

  • in vitroThe stability of KPV in the SH-PGA hydrogel was obviously enhanced, which was presented by detecting its anti-inflammatory activity and promoting cell migration potential after 2 h of exposure to 37 °C7

  • expert opinionKPV is carried into cells by a transporter called PepT1, which normally lives in the small intestine but becomes much more active in the colon during inflammation17

Safety and side effects

Based on 1 in vitro finding and 5 expert opinion findings.

  • in vitroKPV displays a lack of any pigmentory action9

  • expert opinionKPV is not a pharmaceutical drug approved by the FDA18

  • expert opinionFormal safety trials for KPV have not been completed18

  • expert opinionFDA has not identified any human exposure data on drug products containing KPV administered via any route of administration19

  • expert opinionThe result that KPV does not permeate well through skin could limit the systemic toxicity of KPV applied topically to the skin19

  • expert opinionThere have been no human trials, so the safety risks and effectiveness for patients are unknown20

What people use it for

Based on 1 animal finding, 1 in vitro finding, 8 expert opinion findings, 1 anecdotal finding and 2 theoretical findings.

  • animalKPV-Lipos precisely knockdown NLRP3 expression in melanocytes and effectively alleviate vitiligo development3

  • in vitroDCM-KPV enables distinguishing between chronic, acute ulcerative colitis and normal groups via fluorescent imaging8

  • expert opinionKPV and related peptides may be useful alternatives for anti-inflammatory peptide therapy9

  • expert opinionKPV may be useful for treatment of immune-mediated inflammatory skin and bowel diseases, allergic asthma and arthritis9

  • expert opinionThe clearest research focus for KPV is inflammatory bowel disease, including both ulcerative colitis and Crohn's disease18

  • expert opinionResearchers are exploring KPV in wound healing and skin inflammation contexts18

  • expert opinionThere is emerging interest in its possible role in metabolic inflammation and neuroinflammation18

  • expert opinionCompounded KPV is currently available through some pharmacies and research suppliers18

Show 5 more findings

  • expert opinionFDA has been evaluating KPV for wound healing and treating inflammatory conditions such as colitis19

  • expert opinionKPV is being evaluated for wound healing and inflammatory conditions20

  • anecdotalover a year of daily OS-01 peptide use through OneSkin17

  • theoreticalKPV holds potential as a therapeutic agent for preventing environmental pollutant-related skin damage4

  • theoreticalTherapeutic application of KPV as well as KPV-pulsed dendritic cells may be useful for treatment of inflammatory, autoimmune, and allergic diseases13

Other findings

Based on 1 in vitro finding.

  • in vitroDCM-KPV fluorescent probe shows efficient long emission, low photobleaching, negligible cytotoxicity, and high cytocompatibility in living cells8

Points of contention

Where the evidence is unsettled, thin, or says less than the popular claim — worth knowing before you draw conclusions.

Contested

Sources disagree on whether KPV is meaningfully orally bioavailable.

Many vendor/reference sources claim KPV survives GI proteases and is orally bioavailable via PepT1 (KPV — Dosage, Half-Life & Research | Peptide Reference, KPV: α-MSH Tripeptide, FDA Review July 23 2026 | Kalios, KPV Peptide — Anti-Inflammatory Mechanism, Dosing & Side Effects, KPV Peptide: Benefits, Dosage & Safety (2026 Guide), KPV Peptide: What It Is, Benefits, Dosing & Safety, KPV Peptide: Anti-Inflammatory Tripeptide From Alpha-MSH), and animal colitis studies used oral KPV (PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation.). However, a dosing-guide states oral administration is not recommended due to extensive first-pass metabolism and peptidase degradation (KPV (Ac-KPV-NH2) Dosage Guide: How Much Should You Take? (2026)), and a nanoparticle study implies free oral KPV may barely reach the colon (KPV Peptide — Anti-Inflammatory Mechanism, Dosing & Side Effects). A 2017 cadaver-skin study also found topical KPV did not permeate skin well (What to Know About the 6 Peptides Backed by an FDA Advisory Panel).

Limited evidence

No completed human clinical trials or human PK data exist for KPV.

Multiple sources agree the KPV evidence base is entirely in vitro and animal, with zero human clinical trials, no pharmacokinetic data in any species, and no FDA/EMA/Health Canada approval (KPV: α-MSH Tripeptide, FDA Review July 23 2026 | Kalios, KPV Peptide — Anti-Inflammatory Mechanism, Dosing & Side Effects, KPV: Mechanism, Dosing & Evidence (Tier 3) | Pepteligence, KPV Guide | Peptides Defined, FDA Panel Votes To Ease Restrictions on 6 Peptides—But Experts Still Have Major Concerns, KPV Peptide: Benefits, Dosage & Safety (2026 Guide), KPV Peptide: Uses, Safety, and Why the FDA Is About to Review It). The FDA has not identified any human exposure data (What to Know About the 6 Peptides Backed by an FDA Advisory Panel, KPV Guide | Peptides Defined). The one cited human trial actually studied K(D)PT, a related analog, not KPV (KPV Guide | Peptides Defined).

Single source

Dosing and detailed pharmacokinetic figures come largely from one low-tier source with theoretical basis.

Specific bioavailability percentages (85-95% SC, 90-98% IM, 40-60% intranasal, 15-25% topical), peak-concentration times, and 100-1000 mcg/kg murine dose ranges originate from a single tier-3 dosing-guide (KPV (Ac-KPV-NH2) Dosage Guide: How Much Should You Take? (2026)) marked as theoretical/expert opinion, and are not corroborated by the tier-1/tier-2 studies. Dosing ranges also differ across vendor sources (200-500 mcg in KPV — Dosage, Half-Life & Research | Peptide Reference vs 200-1000 mcg in KPV (Ac-KPV-NH2) Dosage Guide: How Much Should You Take? (2026)).

Other

In one cited cancer study, 'KPV' is a mouse genotype label, not the tripeptide.

Vimentin is required for tumor progression and metastasis in a mouse model of non-small cell lung cancer. (PMID 37161053) uses 'KPV' to denote a vimentin-knockout LSL-Kras;Tp53 mouse genotype in NSCLC research; its findings on vimentin, ferroptosis, and withaferin A are unrelated to the Lys-Pro-Val tripeptide that is the subject of the other sources.

Single source

A community-reported adverse event involved mistaken injection of a different peptide.

The one documented safety incident (severe flushing, heart racing, difficulty breathing) reported in KPV Peptide — Anti-Inflammatory Mechanism, Dosing & Side Effects resulted from a user injecting VIP instead of KPV due to similar labelling, not from KPV itself. This is a single anecdotal report.

Using it with other compounds

Check a stack
  • Semax

    Proposed as compatible, but the two compounds' own mechanism data did not support the pairing.

  • TeduglutideComplementary

    No documented conflict

    Both target the gut lining but by entirely different routes: KPV calms mucosal inflammation (NF-κB suppression, reduced colitis severity in animal models), while teduglutide is a GLP-2 agonist that stimulates intestinal epithelial growth and repair. Pairing an inflammation-dampener with a growth/repair signal is a logically complementary approach to restoring a damaged gut barrier, though this combination is only anecdotally supported.

    Tier 4Theoretical — not established

    Shares gut barrier integrity

  • TB-500Complementary

    No documented conflict

    KPV dampens the inflammatory cytokine signal (TNF-α, IL-6, NF-κB), while TB-500 drives the structural side of repair through actin/cytoskeletal dynamics, angiogenesis and cell migration. One quiets inflammation, the other rebuilds tissue — a complementary pairing for wound and mucosal healing.

    Tier 4Theoretical — not established

    Shares inflammation resolution · anti inflammatory · NF kB modulation

  • LL-37Complementary

    Worth caution

    Both have reported antimicrobial and immune-modulating activity but by different means: LL-37 is a cathelicidin that directly disrupts microbial membranes and neutralises endotoxin, while KPV calms the downstream inflammatory response via NF-κB. Together they cover microbial killing plus inflammation control, though LL-37 can be pro-inflammatory and cytotoxic at higher concentrations, so this is a nuanced pairing.

    Tier 4Theoretical — not established

    Shares innate immune · anti inflammatory

  • LactoferrinComplementary

    No documented conflict

    Lactoferrin provides direct antimicrobial defence and iron sequestration at mucosal surfaces, while KPV suppresses the inflammatory cytokine cascade. Both are oriented toward gut/mucosal health from different mechanisms, making them a plausible complementary pair for barrier and microbiome support.

    Tier 4Theoretical — not established

    Shares innate immune · anti inflammatory

  • ThymulinComplementary

    No documented conflict

    Thymulin normalises T-cell balance and suppresses excess proinflammatory cytokines via NF-κB and p38 MAPK inhibition, while KPV independently dampens NF-κB-driven cytokine production. Both converge on restraining overactive inflammation through complementary immune mechanisms (adaptive T-cell tuning vs innate cytokine suppression).

    Tier 4Theoretical — not established

    Shares innate immune · anti inflammatory · NF kB modulation

  • Palmitoyl Tetrapeptide-7Complementary

    No documented conflict

    Both reduce skin inflammation but at different points: palmitoyl tetrapeptide-7 suppresses IL-6/IL-1β in keratinocytes and fibroblasts, while KPV reduces keratinocyte apoptosis and inflammation (including from particulate matter) via NF-κB. In a topical anti-inflammaging context they address overlapping but distinct inflammatory signals.

    Tier 4Theoretical — not established

    Shares anti inflammatory

  • Larazotide AcetateComplementary

    No documented conflict

    KPV calms gut inflammation by suppressing NF-kB and inflammatory cytokines and reduces colitis severity, while larazotide mechanically restores tight-junction sealing. One dampens the inflammatory drivers of leakiness and the other rebuilds the barrier, so they converge on the same goal of gut barrier integrity by different mechanisms.

    Tier 4Theoretical — not established

    Shares gut barrier integrity · anti inflammatory · mucosal repair

  • Thymosin Alpha-1Complementary

    No documented conflict

    KPV is an alpha-MSH fragment that calms inflammation by stabilizing IκBα and blocking NF-κB, with reported antimicrobial and mucosal-repair effects. Thymosin Alpha-1 works through TLR-driven immune coordination and Th1/Th2 balancing. The two lower inflammation by different routes and could complement each other without hitting the same receptor.

    Tier 4Theoretical — not established

    Shares innate immune · anti inflammatory

  • GHK-CuSame downstream effect

    No documented conflict

    Both GHK-Cu and KPV reduce inflammation and lower pro-inflammatory cytokines (IL-6, TNF-α, IL-1β), each acting on NF-κB signaling. GHK-Cu suppresses NF-κB alongside copper-dependent antioxidant enzyme support, while KPV, an α-MSH fragment, stabilizes IκBα and inhibits the IKK complex. They reach an anti-inflammatory endpoint by distinct routes. Nothing described suggests a conflict between them.

    Tier 4Theoretical — not established

    Shares anti inflammatory · NF kB modulation

  • BPC-157Complementary

    No documented conflict

    Both are studied for gut healing and inflammation. BPC-157 provides mucosal cytoprotection and microvascular repair, while KPV suppresses NF-kB and pro-inflammatory cytokines (TNF-alpha, IL-6, IL-1beta) and protects the intestinal epithelial barrier. Different mechanisms converging on gut mucosal recovery, making them a plausible complementary GI pairing.

    Tier 4Theoretical — not established
  • Bremelanotide

    Proposed as compatible, but the two compounds' own mechanism data did not support the pairing.

  • AfamelanotideComplementary

    No documented conflict

    KPV is the C-terminal tripeptide fragment of alpha-MSH and shares afamelanotide's anti-inflammatory arm, but it works mainly by dampening NF- fB-driven cytokines rather than by pigmentation. So a user pairing them would get overlapping anti-inflammatory action from a related molecular family while afamelanotide provides the distinct photoprotection/pigment benefit " understand the anti-inflammatory effects converge and are not strictly additive.

    Tier 4Theoretical — not established

    Shares anti inflammatory

  • ElafinComplementary

    May be complementary

    Both dampen inflammation at mucosal surfaces largely by restraining NF-κB signaling, but by different means: KPV (an α-MSH fragment) suppresses inflammatory cytokines and stabilizes IκBα, while elafin blocks tissue-destroying proteases. In a gut/mucosal setting they address inflammation and barrier protection from complementary angles.

    Tier 3Largely anecdotal — commonly discussed

    Shares innate immune · anti inflammatory · NF kB modulation

  • ImunofanComplementary

    No documented conflict

    KPV is a potent NF-κB-suppressing anti-inflammatory (lowering TNF-α, IL-1β, IL-6) with mucosal/antimicrobial activity, working through a different mechanism than imunofan's thymic immunocorrection. Both push toward calmer inflammation and better mucosal defense, making them a plausible complementary anti-inflammatory pairing.

    Tier 4Theoretical — not established

    Shares innate immune · anti inflammatory

  • Alpha-MSHSame mechanism

    Worth caution

    KPV is literally the C-terminal three-amino-acid tail (Lys-Pro-Val) of alpha-MSH and carries over the parent hormone's anti-inflammatory action — stabilising IκBα and suppressing NF-κB. In fact KPV was developed as the anti-inflammatory 'business end' of alpha-MSH without the pigmentation and appetite effects. Stacking the two for inflammation is largely redundant because they push the same NF-κB brake; alpha-MSH just adds melanocortin-receptor effects (tanning, appetite) that KPV was designed to avoid. Choose based on whether you want those extra effects, rather than combining for additive anti-inflammatory benefit.

    Tier 4Theoretical — not established

    Shares anti inflammatory · NF kB modulation

Safety and side effects

Safety & Side Effects

Human safety data are essentially absent. A general health source19 reports the FDA has not identified any human exposure data on drug products containing KPV administered via any route, and multiple sources18,20 state there are no completed human clinical trials and no pharmacokinetic data in any species. An immune-signaling reference source states KPV is not an FDA-approved consumer medicine and that public claims around gut repair, autoimmune support and skin healing run ahead of direct human clinical evidence(vendor claim). An AI-blog source18 similarly notes formal safety trials have not been completed and that compounded KPV is available through some pharmacies and research suppliers.

Reported side effects

  • A vendor reference page lists common side effects as injection site irritation and mild flushing, with limited human safety data, plus rare risks of allergic reactions and a theoretical risk of weakening the immune system with long-term high doses(vendor claim).
  • A vendor reference page reports that KPV is available as oral capsules from supplement vendors despite the complete absence of human data, and that essentially no side effects are reported at standard doses(vendor claim).

Reported adverse event (mistaken-identity)

  • A vendor reference page documents one safety incident in which a user injected VIP instead of KPV due to similar labelling, causing severe flushing, heart racing and difficulty breathing(vendor claim). This single anecdotal report resulted from injection of a different peptide, not KPV itself.

Basis for the safety assumption

  • A vendor reference page states the safety assumption for KPV rests on it being a fragment of an endogenous hormone and a simple tripeptide of three natural amino acids with no modifications(vendor claim).
  • A general health source19 cites a 2017 study in the Journal of Pharmaceutical Sciences that tested topical KPV on human cadaver skin and found it did not permeate well, which the source suggests could limit the systemic toxicity of topically applied KPV.
  • Several sources2,9 report that, because KPV is described as not engaging melanocortin receptors, it does not cause skin tanning or sexual side effects; note that receptor dependence is itself contested across sources.

Because no human protocol data exist, a peptide reference site notes there is nothing to guide monitoring, dose adjustment, or duration(vendor claim).

Reconstitution and handling

Dosing

No dose has been established for this compound. No regulatory label exists for KPV, and multiple sources agree there are no completed human clinical trials or human pharmacokinetic data. The figures below are what sources report — not guidance — and they disagree with one another.

  • A vendor reference page describes 200–500 mcg subcutaneously daily (or oral for gut applications), typically cycled 4–8 weeks, and lists 99%+ purity(vendor claim).
  • A dosing-guide source lists a range of 200–1000 mcg daily, with most research protocols it cites using 500–750 mcg subcutaneously once daily via 29–31 gauge insulin syringes, and typical cycle lengths of 4–12 weeks (8 weeks most commonly reported)(vendor claim).
  • A dosing-focused blog describes oral/sublingual dosing in the low-milligram range once or twice daily, subcutaneous dosing in the low-microgram to low-milligram range often with cycling, and topical use at low-percentage concentrations, and states dosing frequency is guided by clinical response and delivery format rather than plasma half-life(vendor claim).
  • A dosing-guide source reports murine anti-inflammatory activity at 100–1000 mcg/kg, with optimal efficacy at 500–750 mcg/kg daily(vendor claim). These specific figures originate from a single low-tier theoretical source and are not corroborated by the Tier 1/Tier 2 studies.

Reconstitution

  • A dosing-guide source states subcutaneous protocols typically use a 1–2 mg/mL concentration after reconstitution with bacteriostatic water(vendor claim). As arithmetic about the vial: reconstituting a 5 mg vial with 2.5–5 mL of bacteriostatic water yields roughly 1–2 mg/mL, so a 250 mcg dose corresponds to about 0.125–0.25 mL depending on the concentration chosen.

Route and bioavailability (contested)

  • Many vendor/reference sources claim KPV is orally bioavailable via PepT1 due to its small size and resistance to GI proteases, and animal colitis studies used oral KPV10.
  • Conversely, a dosing-guide source states oral administration is not recommended due to extensive first-pass metabolism and peptidase degradation, and claims 85–95% subcutaneous, 90–98% intramuscular, 40–60% intranasal (twice-daily) and 15–25% topical bioavailability(vendor claim). A nanoparticle study implies free oral KPV may barely reach the colon, having achieved the same effect at 1,200-times-lower dose in a formulated form, and a 2017 cadaver-skin study19 found topical KPV did not permeate skin well.

A dosing-guide source states KPV undergoes rapid enzymatic degradation requiring daily dosing(vendor claim). Because delivery strongly affects exposure, Tier 2 studies have explored sustained-release hydrogel7 and delivery-matrix6 formulations to stabilise KPV for intracolonic administration.

Sources

Ordered by evidence quality — the strongest first.

  1. mechanism of KPV action and a role for MC3R agonists - PMC - NIH(opens in a new tab)
    Tier 1Web · pmc.ncbi.nlm.nih.gov
  2. The neuropeptide alpha-MSH in host defense.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2000
  3. NLRP3 autophagic degradation disruption in melanocytes contributes to vitiligo development.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2026
  4. Lysine-Proline-Valine peptide mitigates fine dust-induced keratinocyte apoptosis and inflammation by regulating oxidative stress and modulating the MAPK/NF-κB pathway.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2025
  5. Vimentin is required for tumor progression and metastasis in a mouse model of non-small cell lung cancer.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2023
  6. A KPV-binding double-network hydrogel restores gut mucosal barrier in an inflamed colon.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2022
  7. Self-Cross-Linked Hydrogel of Cysteamine-Grafted γ-Polyglutamic Acid Stabilized Tripeptide KPV for Alleviating TNBS-Induced Ulcerative Colitis in Rats.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2021
  8. Peptide Receptor-Targeted Fluorescent Probe: Visualization and Discrimination between Chronic and Acute Ulcerative Colitis.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2017
  9. Terminal signal: anti-inflammatory effects of α-melanocyte-stimulating hormone related peptides beyond the pharmacophore.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2010
  10. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2008
  11. alpha-Melanocyte-stimulating hormone, MSH 11-13 KPV and adrenocorticotropic hormone signalling in human keratinocyte cells.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2004
  12. Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2003
  13. New insights into the functions of alpha-MSH and related peptides in the immune system.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2003
  14. Antimicrobial effects of alpha-MSH peptides.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2000
  15. The neuroimmunomodulatory peptide alpha-MSH.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2000
  16. Peptide modulation of inflammatory processes within the brain.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 1998
  17. KPV Peptide: Benefits, Dosage, Safety and What the Research Shows(opens in a new tab)
    Tier 3Web · healnourishgrow.com
  18. KPV Peptide: Uses, Safety, and Why the FDA Is About to Review It(opens in a new tab)
    Tier 3Web · doctronic.ai
  19. What to Know About the 6 Peptides Backed by an FDA Advisory Panel(opens in a new tab)
    Tier 3Web · verywellhealth.com · 2026
  20. FDA Panel Votes To Ease Restrictions on 6 Peptides—But Experts Still Have Major Concerns(opens in a new tab)
    Tier 3Web · health.com · 2026

See something wrong or out of date on this page? Report it.